Ira Zackon, MD, discussed his retrospective study which aimed to understand patient characteristics, treatment patterns, and OS of patients with higher-risk MDS treated in the community oncology setting.
Belong.life Named Among the Leading Digital Health Companies for 2026
The new additions Here is the list of the newcomers: RingConn, RedDrop, YourBio, FusionVital, MediPredict,…